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Breast cancer is a highly heterogeneous disease that can be classified into
multiple subtypes based on the tumor transcriptome. Most of the subtyp-
ing schemes used in clinics today are derived from analyses of microarray
data from thousands of different tumors together with clinical data for the
patients from which the tumors were isolated. However, RNA sequencing
(RNA-Seq) is gradually replacing microarrays as the preferred transcrip-
tomics platform, and although transcript abundances measured by the two
different technologies are largely compatible, subtyping methods developed
for probe-based microarray data are incompatible with RNA-Seq as input
data. Here, we present an RNA-Seq data processing pipeline, which relies
on the mapping of sequencing reads to the probe set target sequences
instead of the human reference genome, thereby enabling probe-based sub-
typing of breast cancer tumor tissue using sequencing-based transcrip-
tomics. By analyzing 66 breast cancer tumors for which gene expression
was measured using both microarrays and RNA-Seq, we show that RNA-
Seq data can be directly compared to microarray data using our pipeline.
Additionally, we demonstrate that the established subtyping method
CITBCMST (Guedj et al., 2012), which relies on a 375 probe set-signature
to classify samples into the six subtypes basL, lumA, lumB, lumC, mApo,
and normL, can be applied without further modifications. This pipeline
enables a seamless transition to sequencing-based transcriptomics for future
clinical purposes.
1. Introduction
Breast cancer is a highly heterogeneous disease with
several clinical subtypes defined by transcriptomic
expression profiles that correlate with pathogenesis,
clinical features, and prognosis (Goldhirsch et al.,
2013; Parker et al., 2009; Stratton et al., 2009). Multi-
ple studies have defined molecular classification
schemes for breast cancer (Cronin et al., 2007; Guedj
et al., 2012; Sorlie et al., 2003; van de Vijver et al.,
2002), most of which are based on transcript quantifi-
cation measured by bead- or probe-based microarrays.
The use of DNA microarrays has been pivotal to can-
cer research for the past decades, but transcriptomics
is moving toward RNA sequencing (RNA-Seq) as this
technique allows for quantification of previously
uncharacterized transcripts, as well as novel genetic
aberrations such as fusion genes and alternative
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splicing (Soneson and Delorenzi, 2013; Vitting-Seerup
and Sandelin, 2017; Zwiener et al., 2014). However,
due to the abundance of useful and widely employed
probe-based subtyping tools, the implementation of
RNA-Seq in clinical settings is falling behind the
implementation in the general research community
(Thompson et al., 2016).
Comparisons of microarray and RNA-Seq transcrip-
tomics have shown that the results of the two tech-
niques are comparable in a general sense and yield
similar results in nonparametric analyses (Chen et al.,
2017; Fumagalli et al., 2014; Marioni et al., 2008;
Uziela and Honkela, 2015), indicating potential for
RNA-Seq to eventually replace microarrays for molec-
ular subtyping. The primary obstacle for the transition
to RNA-Seq transcript quantification in microarray-
based subtyping schemes is the fact that the nature of
the data from these two methods differs vastly.
Because most classification algorithms assume that
training and test data are drawn from the same distri-
bution, a so-called dataset shift occurs when the RNA-
Seq data are submitted directly to algorithms trained
on probe-based expression data. For RNA-Seq data to
be useful for subtyping using algorithms trained on
microarray data, it is therefore necessary that the data
are made comparable in the strictest sense. In order to
facilitate a shift toward sequencing-based transcrip-
tomics in our clinic, we developed an RNA-Seq data
processing pipeline that makes these data compatible
with existing probe-based subtyping methods. We
compared our method to three previously reported
methods for comparing RNA-Seq-based transcrip-
tomics data to microarray-based transcriptomics data:
(a) direct comparison of fragments per kilobase per
million (FPKM) with probe intensities summarized to
transcript level (Chen et al., 2017; Fumagalli et al.,
2014), (b) Training Distribution Matching (TDM)
(Thompson et al., 2016), and (c) Probe Region Expres-
sion estimation Based on Sequencing (PREBS) (Uziela
and Honkela, 2015). We show that our method out-
performs existing methods and enables direct applica-
tion of RNA-Seq data for molecular subtyping of
breast cancer. The method is, in principle, compatible
with all microarray-based cancer subtyping methods.
2. Materials and methods
2.1. Assigning subtypes to samples using
CITBCMST
The CIT Breast Cancer Molecular SubTypes
(CITBCMST) subtyping method employed at our
clinic is a machine learning-based model constructed
on 355 selected samples from primary breast carcino-
mas, which were collected in France in the Cartes
d’Identite des Tumeurs (CIT) program and analyzed
on Affymetrix HG-U133 Plus 2.0 arrays (Guedj et al.,
2012). Using these data, the authors defined a 375
probe set-signature and six distinct molecular subtypes,
basL, lumA, lumB, lumC, mApo, and normL, and
provided a script to assign one of the six subtypes to
new samples profiled using a microarray (Affymetrix
HG-U133 Plus 2.0 or similar). The CITBCMST
method classifies samples based on the intensity of the
375 probe sets using a distance-to-centroid approach,
where each sample is assigned to the subtype with the
closest centroid (per default based on diagonal linear
discriminant analysis). Alternatively, CITBCMST can
classify samples using a 256 HUGO gene symbol sig-
nature summarized from the 375 probes, in which case
the distance to each centroid is calculated as (1—Pear-
son correlation coefficient). No co-normalization or
batch correction is implemented in the CITBCMST
algorithm, but we routinely include these transforma-
tions before classification in clinical practice (Rossing
et al., 2018).
In several parts of the data processing in this study,
we applied the CITBCMST training dataset; the full
dataset (537 CEL files) was downloaded from
ArrayExpress (accession: E-MTAB-365), preprocessed
as described by the authors, and reduced to the 355
core samples used to train the model. We also
removed the AFFX control probe sets before any fur-
ther application.
In order to visualize the subtype calls, CITBCMST
produces two principal component analysis (PCA)
plots of PCs 1 and 2: one for the training data and
one for the test samples. In this study, PCA plots have
been generated using a slightly modified version of the
CITBCMST source code, producing a single plot con-
taining both the training data and the classified sam-
ples. Furthermore, we modified the CITBCMST script
to perform the PCA on the training data and then
subsequently projecting new data into this PC space
by scaling and multiplying the vectors with the rota-
tion, in order to produce comparable PCA plots for
each run of the script.
2.2. Patients, tumor samples and RNA isolation
The test data for this study are comprised of two data-
sets: one generated at the Breast Cancer Translational
Research Laboratory, Institut Jules Bordet, in Brus-
sels, Belgium, published in Fumagalli et al. (2014) con-
sisting of paired microarray and RNA-Seq data
measured in tumors from 57 breast cancer patients,
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and one set consisting of nine tumors for which paired
microarray and RNA-Seq data were generated at
Rigshospitalet (RH), Copenhagen University Hospital,
Denmark.
In the former dataset (henceforth referred to as the
‘Bordet’ dataset), the samples comprise a balanced mix
of the four IHC breast cancer subtypes: 17 triple nega-
tive, 14 HER2 positive, 16 luminal A, and 10 luminal
B patients. In this work, we reclassified the Bordet
samples using the CITBCMST six-class subtyping
scheme (Guedj et al., 2012).
In the latter dataset (henceforth referred to as the
‘RH’ dataset), tumor specimens originated from nine
women diagnosed with breast cancer undergoing pri-
mary surgical procedures (during 2015 and 2016) at
RH. The study was approved by The Danish Data
Protection Agency (jr. no.: 2012-58-0004) and Danish
Breast Cancer Group (jr. no.: DBCG-2015-14),
meaning that tumor material was obtained with the
informed consent of the patients and the study con-
forms to the standards established by the Declara-
tion of Helsinki. Following surgical resection, fresh
tumor specimens were evaluated by designated
pathologists and tumor biopsies (~ 100 mg) were
stored in RNAlater (Thermo Fisher Scientific,
Waltham, MA, USA). RNA was isolated using the
AllPrep DNA/RNA purification kit (Qiagen, Hilden,
Germany) and the QIACube workstation according
to the manufacturer’s instructions. The integrity of
the RNA was measured using the Agilent RNA
6000 Nano Kit on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Inc., Santa Clara, CA, USA).
2.3. Microarray analysis
For the Bordet dataset, the transcriptomic profiles were
obtained using the Affymetrix HG-U133 Plus 2.0
microarray. The raw Affymetrix cell intensity files (.CEL
files) files are available on the NCBI Gene Expression
Omnibus under accession number GSE43358.
To generate the RH dataset, RNA was reverse
transcribed and used for cRNA synthesis, and label-
ing and hybridization with the Affymetrix HG U133
Plus 2.0 microarray were carried out according to
the manufacturer’s protocol. The arrays were washed
and stained with phycoerythrin-conjugated strepta-
vidin using the Affymetrix Fluidics Station 450, and
arrays were scanned in the Affymetrix GeneArray
3000 7G scanner. CEL files were generated in the
GeneChip Command Console Software (AGCC;
Affymetrix, Thermo Fisher Scientific). For both
datasets, quality control (QC) was performed using
the R/Bioconductor package affyQCReport. After
passing QC, the raw. CEL-files were processed using
robust multi-array average (RMA) from the R/Bio-
conductor package affy (Gautier et al., 2004) unless
otherwise indicated. Finally, the data were reduced
to contain only the 54 613 noncontrol probe sets.
2.4. RNA sequencing
The Bordet dataset was sequenced on the Illumina HiSeq
2000 (Illumina, Inc., San Diego, CA, USA) as described
in (Fumagalli et al., 2014) and was archived at the Euro-
pean Genome-phenome Archive (EGA) under accession
number EGAD00001000627.
RNA sequencing for the RH dataset was done using
TruSeq Stranded Total RNA Library Prep Kit, and
RNA was paired-end sequenced on a NextSeq500
(Illumina, Inc.) to gain an average output of 50–100 M
reads. Raw sequencing data from the Illumina
sequencing platforms were processed with CASAVA-
1.8.2. FastQC (Andrews, 2010) was run on all samples
to ensure a proper quality before further processing
(Conesa et al., 2016).
2.5. Estimating target sequence abundance from
RNA sequencing reads
2.5.1. Fragments per kilobase per million
Raw reads were trimmed using Trimmomatic (Bolger
et al., 2014) with settings LEADING:3 TRAILING:3
SLIDINGWINDOW:4:15 MINLEN:36. The trimmed
reads were mapped to the human reference genome hg19
using TopHat2 (v. 2.1.1) (Kim et al., 2013), and Cuf-
flinks (v. 2.2.1) (Trapnell et al., 2010) was used for gene
expression quantification. Both processes used the anno-
tation file (.GTF) from Ensembl (Zerbino et al., 2018).
FPKM values for all genes were extracted from the
genes.fpkm_tracking files and merged to a table for all
samples, and FPKMs for duplicate genes were summed
using ddply from the R package plyr (Wickham, 2011).
This resulted in a total of 63 657 transcripts, for which
the FPKM values were log-transformed using the for-
mula FPKM
0
= log2(FPKM + 1).
2.5.2. Transcripts per million
Reads were mapped using kallisto (Bray et al., 2016),
which produces transcripts per million (TPM) as units
of abundance, by estimating the proportion of reads
mapping to the target sequence. Briefly, kallisto uti-
lizes so-called pseudoalignment, which is based on
exact matching of k-mers derived from reads, rather
than traditional sequence alignment. This speeds up
2138 Molecular Oncology 12 (2018) 2136–2146 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Probe-based cancer subtyping using RNA-Seq data C. B. Pedersen et al.
read mapping significantly and in some cases provides
more accurate mapping than traditional approaches.
The applied reference was the HG-U133 Plus 2.0 Tar-
get Sequences, originally retrieved from www.affyme
trix.com (a copy of this file as well as the mapping
index file is available on https://bitbucket.org/cbligaa
rd/rnabc/downloads). Each target sequence represents
a probe set on the microarray, and individual probes
in a given probe set are selected as subsequences of the
target sequence.
2.6. Comparing microarray and RNA sequencing
data
According to the CITBCMST classification protocol,
the optimal data input is RMA normalized microar-
ray data from an Affymetrix platform. However, the
consensus on best practices handling of microarray
data suggests normalization of intensity distributions
and correction of batch effects between runs from dif-
ferent instruments, times, or operators (Johnson
et al., 2007). In clinical practice, we routinely include
these transformations before classification (Rossing
et al., 2018). In this study, we compared four differ-
ent processing pipelines for making subtyping results
from the microarray and RNA-Seq platforms compa-
rable—three of these were previously published, and
in those cases, the processing described by the origi-
nal authors was followed as closely as possible,
despite this meaning that microarray data were not
always processed according to the described best
practices.
2.6.1. Direct comparison of transcript-summarized probe
intensities with transcript FPKM (Fumagalli)
Both data types were processed as described by
Fumagalli et al. (2014). For microarray data, frozen
RMA was applied using the R/Bioconductor package
frma (McCall et al., 2010). To allow for direct com-
parison to RNA-Seq expression levels, jetset (Li
et al., 2011) was used to map between HUGO sym-
bols and probe set IDs. If multiple probe sets mapped
to the same gene, the one with the highest jetset score
was chosen. For RNA-Seq, starting with log-trans-
formed FPKM values, a translation of Ensembl gene
IDs to HUGO symbols was performed using BioMart
(Durinck et al., 2005). If a single HUGO symbol
matched more than one Ensembl gene ID, the sum of
the values for the corresponding gene was used. The
CITBCMST classifier was then applied on the HUGO
symbols (238/256 HUGO symbols were accepted by
CITBCMST).
2.6.2. Training Distribution Matching (TDM)
The TDM algorithm (Thompson et al., 2016) was
developed to enable comparison of sequencing-based
and probe-based transcriptomics data. Briefly, TDM
leaves between-sample relationships intact, but trans-
forms the distribution to be similar to that of the
training data. The rank order of most genes remains
the same in order to not affect any biological signifi-
cance found herein. The distribution is adjusted for an
entire test dataset, in order to avoid overnormalization
from adjusting per sample, and it includes a log2 trans-
formation as microarray data are typically trans-
formed as such.
The RNA-Seq data were processed as described
above, except that we utilized untransformed FPKM
values as described by Thompson et al. (2016). We
used the same HUGO translation from the Ensembl
IDs and then used jetset on the full CITBCMST train-
ing dataset and the Bordet arrays to get corresponding
genes before running TDM against the translated ‘full’
CITBCMST training dataset (18 734 genes included).
We then performed CITBCMST classification on the
RNA-Seq data using 234 HUGO symbols and directly
on RMA normalized microarray data. The correlation
of transcript abundance was calculated using the full
set of matching genes with the Bordet data.
2.6.3. Probe Region Expression estimation Based on
Sequencing (PREBS)
Briefly, the PREBS pipeline utilizes the mapped reads
from each file stored in BAM format generated by
standard alignment algorithms such as TopHat.
PREBS then counts the number of reads overlapping
transcript regions corresponding to probe sequences in
order to estimate probe region expression (Uziela and
Honkela, 2015). Microarray data were simply RMA
normalized before subtyping.
2.6.4. Mapping RNA-Seq reads directly to microarray
probe sequences (RNABC)
Reference transcripts are commonly extracted from a
reference genome such as hg19, but instead, we used
the target sequences of the Affymetrix HG-U133 Plus
2.0 array as reference, such that the abundance esti-
mates from RNA-Seq data can be compared directly
to the intensities from specific probes on the microar-
ray platform. After removing control probe sets, ‘nor-
malize.quantiles.target’ from the R/Bioconductor
package ‘preprocessCore’ was used to quantile normal-
ize the probe set sequence-aligned TPM units using the
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distribution of the mean intensity of all probes in the
full CITBCMST training dataset as the target distribu-
tion. After quantile normalization, ‘ComBat’ (Johnson
et al., 2007) (from the R/Bioconductor package ‘sva’)
was applied to remove batch effects between the
CITBCMST training dataset and the test data. We
named our pipeline RNA Breast Cancer (‘RNABC’).
This pipeline was followed by CITBCMST subtyping
on the probe set-level. For consistency, we treated the
microarray data in the exact same manner.
2.7. Performance metrics
The CITBCMST predictor produces a confidence score
for each sample assignment: If a sample is close to sev-
eral centroids, that is, the difference in distance from a
sample to two or more of the centroids is smaller than
the tenth percentile of the distances between the cen-
troids in the training dataset, the score is set to
‘mixed’. If this is not the case, the score is set to either
‘core’ or ‘outlier’ depending on the distance to the
closest centroid. If the distance is n times larger than
the median absolute deviation (MAD) between the
training data and the centroid for the given sub-
type, the sample is classified as an ‘outlier’. n is calcu-
lated as the maximum between the six subtypes of the
value (maxdistances to centroid - meddistances to centroid)/
maddistances to centroid (Guedj et al., 2012).
Performance was assessed by the number of perfect
matches between the microarray predicted subtypes
and the RNA-Seq predicted subtypes, and the number
of mismatches. We consider two types of mismatches:
confidence mismatch (between ‘core’, ‘outlier’, or
‘mixed’ confidence label) and class mismatch (between
either one of the subtypes)—the latter of course being
the more severe error.
Additionally, we calculated the R2 value for the least
squares regression for microarray probe set intensities
vs. RNA-seq FPKM/TPM and the Spearman’s Rho
for a rank-based measure of correlation, as we cannot
expect probe set intensities and FPKM/TPM to corre-
late linearly for all preprocessing methods.
3. Results
3.1. Transformation of RNA sequencing data for
use with the CITBCMST classifier
In order to define the most accurate processing proce-
dure, we tested multiple combinations of RNA-Seq
metrics, normalization, and batch correction—includ-
ing existing methods for RNA-Seq and microarray
data comparison. We found that mapping RNA-Seq
reads to the array probe set sequences (rather than a
reference transcriptome), followed by quantile normal-
ization to a target distribution consisting of the mean
probe intensities in the microarray training data, fol-
lowed by batch correction with the microarray training
data (Fig. 1) resulted in a very high correlation
between microarray- and RNA-Seq-based abundances
(R2 = 0.9445 and Spearman’s q = 0.9638) and highly
similar subtyping (identical for 51 of the 57 samples)
compared with the subtyping on the corresponding
microarray data. The RNABC pipeline is implemented
in the R programing language (R Core Team, 2018)
and available at https://bitbucket.org/cbligaard/rnabc/.
3.2. Validation of the RNABC pipeline on the
Bordet dataset
The RNABC pipeline resulted in 51 out of the 57 paired
samples matching on predicted CITBCMST subtype,
while the remaining six samples were mismatches. For
the six discordant samples, additional analyses were per-
formed to examine the reason for the mismatch. A
CITBCMST prediction for each of six samples was per-
formed and the results visualized (Fig. 2). In the case of
‘HER2-15’, ‘HER2-19’, ‘LUMA-26’, ‘LUMA-31’, and
‘LUMB-03’, the errors are very small since the samples
are predicted to be mixed using one of the data types and
core using the other data type (confidence mismatches).
In these five cases, the Spearman’s Rho values for the
two data types are above 0.95 and the points are very
close in the PC space as shown in Fig. 2. In the final case,
‘LUMA-04’, the distance between the two points in PC
space is more substantial (class mismatch). When investi-
gating this further, there were no signs of poor data qual-
ity on either the microarray or RNA-Seq level; however,
the Spearman’s Rho between the microarray and RNA-
Seq data is 0.9152, which is the lowest correlation of all
the paired samples. Furthermore, for the 375 probes
actually included in CITBCMST classification, the Spear-
man correlation is only 0.8337. The problem with a lower
Spearman correlation for the 375 probes is not a general
trend across the samples, so it would appear that this
sample is an outlier case, in which concordance between
the two data types is low for reasons unexplained by
standard QC measures.
3.3. Validation of the RNABC pipeline on the RH
dataset
To ensure more general applicability, a second dataset
of nine samples was used to validate the performance
of the pipeline. Beyond these being data generated at
our clinic, validating on a smaller dataset is relevant
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since in clinical settings data are typically submitted in
smaller batches of samples, which may affect the
results of the batch correction step. For the RH data,
the Spearman’s Rho between the data types after
RNABC transformation was 0.9734 (0.5722 before
running the RNABC pipeline) and seven out the nine
samples were predicted to be of the same subtype for
both data types (Fig. 3). The two mismatches are both
confidence mismatches: one sample was classified as
lumA using microarray data and lumAB mixed based
on RNA-Seq data, and the other case is a switch from
basL core to basL-mApo mixed. Such minor discrep-
ancies between data types in the subtyping of border-
line cases can arise from minor variations, and we
categorize the mixed cases as inconclusive for down-
stream clinical decision-making regardless.
3.4. Comparison with other methods
The performance of the three other methods for compar-
ing microarray data and RNA-Seq data was also assessed
on the Bordet dataset. The results of three methods and
Fig. 1. Pipelines for using CITBCMST classifier using (A) microarray data and (B) RNA-Seq data with the RNABC pipeline. For microarray
data, processed samples are submitted to the CITBCMST R package and the resulting subtype predictions are returned. In the RNABC
pipeline, raw RNA-Seq data are submitted, reads are mapped to probe target sequences using kallisto, read counts are quantile normalized
and batch corrected using the CITBCMST training data (n = 355) as comparison, and classification is done on transformed counts.
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the RNABC pipeline are summarized in Fig. 4. The
Spearman’s rank correlation is fairly good in all cases
with values of 0.9638, 0.8191, 0.8206, and 0.7306 for the
RNABC, Fumagalli, TDM, and PREBS methods,
respectively, which means that the data are comparable
in a general sense, but as evident from Fig. 4, using
RNA-Seq data without further processing as input to a
prediction algorithm trained on microarray probe
intensities yields suboptimal results. In terms of R2,
Spearman’s Rho, and subtype matches, the RNABC
pipeline proved superior to all other tested methods.
Also worth noting is that the runtime of the
RNABC pipeline is a fraction of the other three tested
methods, mostly owing to the speed of the kallisto
algorithm. Not only does kallisto eliminate the need
for traditional read mapping algorithms in the pipeline
as reads are pseudoaligned directly against the probe
sequences, but postprocessing (normalization and
batch correction) is also near-instantaneous, bringing
the runtime down from hours to minutes per sample
on a standard laptop computer.
4. Discussion
4.1. Discordance between subtyping using
microarray and transformed RNA sequencing
data
Some of the samples are almost equally close to two sub-
types. Because of this uncertainty, these borderline cases
receive a less meaningful class assignment than the core
samples clearly belonging in a single subtype. Even minor
differences in true and estimated probe abundance can
contribute to class switching in the mixed cases, and clini-
cally speaking, these classifications are not used. Samples
that do not fit well into any of the subtypes also represent
classifications without clinical utility. Both the outlier
and the mixed cases point out a weakness of the entire
subtyping paradigm in precision medicine. Every cancer
patient is unique and even two patients that are predicted
to be of the exact same subtype may be quite different on
a molecular level. This lack of robustness should certainly
be improved on, but this should be addressed by improv-
ing subtyping methods as well as patient stratification
and treatment in general.
4.2. Importance of pipeline components
The RNABC pipeline consists of three main components:
the mapping of RNA-Seq reads to probe set target
sequences, quantile normalization to the CITBCMST
training dataset, and batch correction to the CITBCMST
training dataset. The first step, the mapping of the RNA-
Seq reads directly to the probe set target sequences,
allows for subtyping including all the 375 probe sets used
as the original CITBCMST subtype signatures. This
makes the subtyping more robust, than applying the
CITBCMST classifier on the 256 HUGO symbol signa-
ture. With the goal of reproducing the microarray-based
subtyping from the RNA-Seq data, both quantile nor-
malization and batch correction are essential components
of the pipeline. Probe set mapping alone results in no
Fig. 2. PCA plot of the CITBCMST training data (circles) and the six discordantly classified samples of the Bordet dataset from both
microarray (squares) and RNA-Seq (triangles) data. Each sample point is labeled by the original sample name from Fumagalli et al. (2014) to
allow for direct comparisons between sample pairs.
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matches, as a result of poor correlation between microar-
ray and RNA-Seq data (R2 = 0.0119, SCC = 0.6982),
while quantile normalization alone following probe set
mapping results in five matches (R2 = 0.5540) in the
CITBCMST subtyping for the Bordet dataset, and batch
correction following probe set mapping yields only mis-
matches (R2 = 0.0118). These results indicate that the
application of mapping and both postmapping steps is
necessary to ensure high accuracy of the classification.
Interestingly, each of the two postmapping steps alone
yields Spearman’s rank correlation coefficients (SCC) of
0.6977 and 0.8796, respectively, which corresponds well
to the observation in section 3.4 that a near-identity
relation is necessary to reproduce microarray-based
subtyping results. Finally, it should be emphasized that
high-quality data are paramount for obtaining accurate
subtyping results, meaning that thorough QC is recom-
mended before running this (or any other) pipeline.
4.3. Data transformation and batch correction
In this study, we transform RNA-Seq data to match
the distribution of the entire CITBCMST training
dataset, which contains 355 samples of six different
subtypes. This means that transforming the test data
to the entire CITBCMST training data distribution
can potentially introduce errors if the test data do not
contain all six subtypes. Additionally, considering that
samples in the clinical setting might be run individu-
ally, there is an even higher risk of transforming the
data incorrectly. We recommend that samples always
be run in batches for clinical applications. Alterna-
tively, if it is not possible to obtain a balanced sample
cohort, an option is to run the ComBat batch correc-
tion while accounting for covariates such as receptor
status. The receptor status for all samples in the
CITBCMST training dataset is available in the
RNABC Bitbucket repository.
4.4. CITBCMST subtyping
The CITBCMST subtyping algorithm is only one of
numerous breast cancer subtyping algorithms, and
additional algorithms exist for other cancer types. This
microarray-based subtyping scheme was implemented
in our laboratory and enabled consecutive molecular
subtyping for informing clinical decision-making, as
well as a full transcriptome for downstream explo-
rative analyses. There is, however, room for improve-
ment of the algorithm, and we tweaked several
methodological steps in this study. Most notably, the
standard implementation does not perform batch cor-
rection, which we and others have shown drastically
improves the ability to compare datasets. The recalcu-
lation of the PCA with the test set is also somewhat
suboptimal (although strictly an aesthetic parameter)
as each run will produce a different plot. Instead, we
suggest projecting new samples in to a PC space pre-
calculated on the training data, in order to ensure con-
sistency in the output. In general, the robustness of the
algorithm could also be improved upon. For this, a
complete reworking of the subtyping scheme is proba-
bly necessary—preferably using RNA-Seq data as a
starting point. Until such time, our RNABC pipeline
enables the utility of legacy microarray-based subtyp-
ing methods.
Fig. 3. PCA plot of the CITBCMST training data (circles) and the nine samples of the RH dataset from both microarray (squares) and RNA-
Seq (triangles) data. Each sample point is labeled by a number to allow for direct comparisons between sample pairs.
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4.5. Future perspectives
It should be noted that many different breast cancer
subtyping schemes exist besides CITBCMST. The
choice of subtyping scheme is not standardized, and the
arguments for using one or the other may be based on
experience with different approaches in a particular
clinic. The lack of robustness of many existing subtyp-
ing methods calls for creating entirely new schemes for
cancer subtyping based on high-throughput sequencing,
Fig. 4. Comparison of RNABC and three other methods for comparing microarray data and RNA-Seq data applied on the Bordet dataset. All
plots represent the data after transformation. Each column represents a method, and the rows, from top to bottom, represent (A) a density
plot of the distribution of the two data types across all 57 patients including all available probe sets/genes, (B) a density scatter plot for
expression values for all available probe sets/genes, and (C) a density scatter plot for the probe sets/genes used in the actual subtyping
with CITBCMST. The black dashed lines in B and C represent the least squares regression line, and the R2 value for this line is printed in
the top corner along with SCC for the datasets. (D) Percentages of matches and mismatches when comparing the CITBCMST prediction for
microarray and RNA-Seq data. For RNABC and PREBS, the total number of probe sets was 54 613 (all probe sets from the Affymetrix HG-
U133 Plus 2.0 Array except for the control probe sets) and the number used for subtyping was 375. For Fumagalli and TDM, the total
number of genes was 18 734, and 238 and 234 were used in subtyping, respectively.
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possibly including biomarkers from other omics data
types, and ideally some form of patient immune profil-
ing as well. The subtypes of the future algorithms can of
course remain the same, and the training data could be
switched using paired samples of training data, possibly
with multiple replicates to ensure reliability. Having
clinics phase out microarray analysis altogether requires
strong scientific evidence that RNA-Seq-based subtyp-
ing can perform equally well or better than current
methodologies. Despite the current challenges, more
studies demonstrating the utility of RNA-Seq are con-
tinuously conducted indicating a promising future for
RNA-Seq in clinical medicine. Hopefully, the increasing
use of RNA-Seq and this contribution to its utility will
lead to new insights and inspire novel treatment
options.
5. Conclusion
Molecular subtyping of cancer for clinical decision-
making is common practice for many cancer types.
The majority of these tools are built from DNA
microarray profiling of large cohorts of patients—in
many cases through massive collaborative efforts—and
the resulting classifications serve as international clini-
cal standards. Gene expression profiling is to an
increasing degree being performed using RNA-Seq,
but while the two data types are comparable in non-
parametric analyses of transcript abundance, RNA-
Seq count data are not directly compatible with estab-
lished probe intensity-based subtyping methods.
We here present a method that enables fast and
accurate subtyping of tumor samples for which gene
expression is measured using RNA-Seq. We tested our
method on 66 breast cancer samples for which we have
measured transcript abundance using both microarrays
and RNA-Seq, and were able to achieve near-perfect
correlation between probe intensities from microarrays
and the probe-level expression inferred from RNA-Seq
data (R2 = 0.9445, Spearman’s q = 0.9638) and near
perfectly matched breast cancer subtype assignments
from the microarray data using the corresponding
RNA-Seq data. We compared our method to three
state-of-the-art methods for comparison of the two
data types and outperform them all significantly, as no
existing tool is able to generate data comparable
enough to enable accurate clinical subtyping. Further-
more, since we utilize pseudoalignment directly to the
probe sequences, we circumvent traditional read align-
ment and thereby cut the processing time down from
more than 3 h to < 3 min per sample on a standard
laptop. The tool is freely available at https://bitbucket.
org/cbligaard/rnabc/.
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